0 228

Cited 25 times in

Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study

 Yoon Suk Jung  ;  Minkyung Han  ;  Won Ho Kim  ;  Sohee Park  ;  Jae Hee Cheon 
 DIGESTIVE DISEASES AND SCIENCES, Vol.62(8) : 2102-2112, 2017 
Journal Title
Issue Date
Adolescent ; Adrenal Cortex Hormones/therapeutic use ; Adult ; Aged ; Biological Products/therapeutic use ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/epidemiology* ; Colitis, Ulcerative/surgery ; Crohn Disease/drug therapy ; Crohn Disease/epidemiology* ; Crohn Disease/surgery ; Databases, Factual ; Digestive System Surgical Procedures/statistics & numerical data ; Disease Progression ; Female ; Humans ; Immunologic Factors/therapeutic use ; Incidence ; Male ; Middle Aged ; Republic of Korea/epidemiology ; Young Adult
Clinical course ; Crohn’s disease ; Incidence ; South Korea ; Ulcerative colitis
BACKGROUND: The incidence of inflammatory bowel disease (IBD) is increasing in East Asia; however, population-based data from this region are lacking. AIM: We conducted a nationwide, population-based study to examine the incidence and disease course of IBD in South Korea. METHODS: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD [10,049 with ulcerative colitis (UC) and 5595 with Crohn's disease (CD)] from 2011 to 2014. RESULTS: During the study period, the average annual incidence of UC was 5.0 per 105, while that of CD was 2.8 per 105. Among patients with UC, the cumulative rates of surgery 1 and 4 years after diagnosis were 1.0 and 2.0%; those among patients with CD were 9.0 and 13.9%, respectively. The 1- and 4-year cumulative rates of moderate- to high-dose corticosteroid use were, respectively, 26.6 and 45.2% among patients with UC, and 29.9 and 50.8% among those with CD. Similarly, the 1- and 4-year cumulative rates of immunomodulator use were 14.1 and 26.4% among patients with UC, and 58.3 and 76.1% among those with CD, respectively. With regard to biologic use, the 1- and 4-year cumulative rates were 3.0 and 9.0% among patients with UC, and 11.1 and 31.7% among those with CD, respectively. CONCLUSIONS: The recent incidence of IBD in South Korea has been the highest in East Asia. Patients who had been diagnosed recently with IBD showed lower rates of surgery and higher rates of immunomodulator and biologic use compared to those reported ever in South Korea.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
4. Graduate School of Public Health (보건대학원) > Graduate School of Public Health (보건대학원) > 1. Journal Papers
Yonsei Authors
Kim, Won Ho(김원호) ORCID logo https://orcid.org/0000-0002-5682-9972
Park, So Hee(박소희) ORCID logo https://orcid.org/0000-0001-8513-5163
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
Han, Minkyung(한민경) ORCID logo https://orcid.org/0000-0002-5011-5557
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.